By making blood vessels tighten, the angiotensin-converting enzyme (ACE) indirectly raises blood pressure. Angiotensin I is changed by ACE into angiotensin II, which tightens the blood vessels. The renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body, is made up of ACE, angiotensin I, and angiotensin II. Cells in the endothelium (inner layer) of blood vessels secrete ACE in the lungs and kidneys.It serves two main purposes: In a substrate concentration-dependent manner, ACE catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Bradykinin, a potent vasodilator, and other vasoactive peptides are broken down by ACE. In order to treat conditions like high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus, ACE inhibition is a goal. By inhibiting ACE (using ACE inhibitors), angiotensin II production and bradykinin metabolism are reduced, which causes a systematic dilation of the arteries and veins and a reduction in arterial blood pressure.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V87314 | (±)8(9)-EpETE | 851378-93-3 | (±)8(9)-EpETE ((±)8,9-EEQ; (±)8,9-epoxy Eicosatetraenoic acid) can be converted to epoxyeicosatetraenoic acid (EpETE) by multiple cytochrome P450 isozymes. |
|
V16693 | trans-4-Hydroxytamoxifen | 68047-06-3 | 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally bioavailable, selective estrogen receptor modulator (SERM). |
|
V85768 | Abz-LFK(Dnp)-OH | 1217437-30-3 | |
|
V85747 | Abz-SDK(Dnp)P-OH | 860313-53-7 | |
|
V50469 | AD-012 | 3010931-94-6 | AD012 is a cACE/NEP dual inhibitor. |
|
V50460 | AD-013 | 3010931-81-1 | AD013 is a cACE/NEP dual inhibitor. |
|
V72991 | Alamandine | 1176306-10-7 | Alamandine is a vasoactive peptide, a member of the renin-angiotensin system (RAS), and an endogenous ligand of the G protein-coupled receptor MrgD. |
|
V87311 | BKIDC-1553 | 1951431-34-7 | BKIDC-1553 is an orally available antiglycolytic agent and kinase inhibitor derivative with a predicted half-life of approximately 17 h in humans. |
|
V87319 | Canvircept | Canvircept is a monoclonal antibody against ACE2. | |
|
V87321 | Casein hydrolysate | 65072-00-6 | Casein hydrolysate is the hydrolysis product of casein. |
|
V95275 | Cilazapril hydrochloride | 88824-78-6 | Cilazapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and congestive heart failure. |
|
V87317 | Cilazaprilat | 90139-06-3 | Cilazaprilat (Ro 31-3113) is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 0.7 nM for rat enzyme) and an active metabolite of Cilazapril. |
|
V94258 | Deserpidine hydrochloride | 6033-69-8 | Harmonyl hydrochloride is an antihypertensive compound that competitively inhibits the activity of angiotensin-converting enzyme (ACE). |
|
V100430 | Epicaptopril | 63250-36-2 | Ecaptopril (SQ 14534) is a derivative of captopril. |
|
V25708 | MLN-4760 | 305335-31-3 | MLN-4760 is a novel, potent and selective human angiotensin-converting (ACE2) inhibitor with IC50of 0.44 nM and with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA;IC50, 27 μM). |
|
V94512 | Moveltipril calcium | 85921-53-5 | Movipril calcium (MC-838 calcium) is an oral angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. |
|
V84879 | Oleacein | 149183-75-5 | |
|
V105630 | Quinapril | 85441-61-8 | Quinapril is an oral, nonpeptide and nonthiol angiotensin-converting enzyme (ACE) inhibitor. |
|
V87316 | Quinaprilat hydrochloride | 82586-58-1 | Quinaprilat hydrochloride is an orally active non-thiol angiotensin converting enzyme (ACE) inhibitor and the active metabolite of Quinapril. |
|
V107903 | Ramipril diketopiperazine | 108731-95-9 | Ramipril diketopiperazine is an impurity in the angiotensin-converting enzyme (ACE) inhibitor ramipril. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
